

REPLIGEN CORP  
Form 8-K  
September 10, 2007

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT**  
**TO SECTION 13 OR 15(D) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): September 10, 2007

**REPLIGEN CORPORATION**

---

(Exact Name of Registrant as Specified in Its Charter)

**DELAWARE**

---

(State or Other Jurisdiction of Incorporation)

**0-14656**

**04-2729386**

---

(Commission File Number)

(IRS Employer Identification No.)

**41 Seyon Street, Building #1, Suite 100,**

**Waltham, Massachusetts**

---

**02453**

Edgar Filing: REPLIGEN CORP - Form 8-K

(Address of Principal Executive Offices)

(Zip Code)

(781) 250-0111

---

(Registrant's Telephone Number, Including Area Code)

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**INFORMATION TO BE INCLUDED IN THE REPORT**

**Item 1.01. Entry into a Material Definitive Agreement**

On September 10, 2007 (the Effective Date ), Repligen Corporation ( Repligen ) and the Massachusetts Institute of Technology ( MIT ) entered into a settlement agreement (the Settlement Agreement ) with ImClone Systems, Incorporated ( ImClone ) relating to the lawsuit against ImClone for infringement of U.S. Patent No. 4,663,281 based on ImClone s manufacture and sale of Erbitu®. The Settlement Agreement provides for ImClone to make a payment of \$65 million to co-plaintiffs Repligen and MIT and will result in net proceeds to Repligen of approximately \$40 million after payment of obligations to MIT and legal expenses. The Settlement Agreement serves as the basis for Repligen and MIT to dismiss the lawsuit against ImClone and Repligen has granted ImClone a non-exclusive sublicense to certain patent rights.

In May 2004, Repligen and MIT filed an action in the United States District Court for the District of Massachusetts against ImClone for infringement of U.S. Patent No. 4,663,281 based on ImClone s manufacture and sale of Erbitu®. The patent, which covers the use of certain genetic elements that increase protein production in a mammalian cell, is assigned to MIT and exclusively licensed to Repligen.

**Item 7.01. Regulation FD Disclosure**

On September 10, 2007, Repligen announced in a press release that on September 10, 2007, Repligen, MIT and ImClone executed a Settlement Agreement, which serves as the basis for Repligen and MIT to dismiss all patent litigation against ImClone and Repligen has granted ImClone a non-exclusive license to certain patent rights. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information and the exhibit attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

d) Exhibits.

99.1 Press Release issued by Repligen Corporation on September 10, 2007

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**REPLIGEN CORPORATION**

Date: September 10, 2007

By: /s/ Walter C. Herlihy  
Walter C. Herlihy

Chief Executive Officer and President

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release issued by Repligen Corporation on September 10, 2007